Anti-Mouse/Human CD45R (B220) (Clone RA3-6B2) - Purified In vivo GOLD™ Functional Grade

Antibody Details

Product Details

Reactivity Species

Mouse/Human

Host Species

Rat

Immunogen

Abelson murine leukemia virus-induced pre-B tumor cells

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Next Day Ambient

RRID

AB_2737486

Applications and Recommended Usage
Quality Tested by Leinco

FC The suggested concentration for this RA3-6B2 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature

Act
CODEX®
CyTOF®
Depletion
FA
IHC (Frozen)
IHC (Paraffin)
IP

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone RA3-6B2 recognizes the B-cell determinant (Mr 220 kD) of the CD45 molecule.

Antigen Distribution

The CD45R antigen is present on mouse B-cells, B-cell precursors and lytically active subsets of lymphokine-activated killer cells (NK cells and non-MHC restricted CTL).

Background

CD45 is a 180-240kD glycoprotein member of the protein tyrosine phosphatase (PTP) family known for its involvement in regulating a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. CD45 and its isoforms are vital regulators of T- and B-cell antigen receptor signaling. CD45 functions through its extracellular domain or through its cytoplasmic domain, and serves as a negative regulator of cytokine receptor signaling via JAK kinase supression. The large extracellular domain is highly glycosylated, and its multiple isoforms allow extensive variation in the structure of its side chains. CD45 isoforms show cell-type and differentiation-stage specific expression that can be used as markers that identify and distinguish between different types of immune cells. CD45R is an isoform of CD45 with a molecular weight of 220 kD. CD45R contains all three possible exons (A, B, and C); making it the longest protein generated from alternative splicing with a migration at 200 kD when isolated from T cells. Furthermore, B cells express CD45R with heavier glycosylation, bringing the molecular weight to 220 kD, hence the name B220. Notably, B220 expression is not only restricted to B cells and may also be expressed on activated T cells, on a subset of dendritic cells, and on other antigen-presenting cells. Additionally, activated and memory T lymphocytes express CD45RO which facilitates T cell activation. CD45RO lacks all three possible exons (A, B, and C), making it the shortest CD45 isoform.

Antigen Details

Protein

CD45R

Ligand/Receptor

Galectin-1, CD2, CD3, CD4

Function

Phosphatase, T and B cell activation

PubMed

CD45R

NCBI Gene Bank ID

19264 5788

UniProt.org

Information on Uniprot.org

Research Area

Cell Biology

.

Immunology

.

Inhibitory Molecules

.

Neuroscience

.

Neuroscience Cell Markers

References & Citations

1.) Coffman, B. et al. (1982) Immunological Rev. 69:5

2.) Zuhair, K. et al. (1993) J. Immunol. 150:17

3.) Asensi, V. et al. (1989) Immunology 68:204

4.) Gubin et al. (2018) Cell. 175:1014–1030 Journal Link

Technical Protocols